Physician profile
Sofie Pinney
NPI 1063844322
$130,389.59
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $2,223 · 2021: $2,352 · 2022: $23K · 2023: $17K · 2024: $42K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $18K · Food and Beverage: $3,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,933.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,720.00 |
| Travel and Lodging | $18,024.64 |
| Food and Beverage | $3,781.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $53,696.83 | 2021-2025 | Hoffmann, Ortholoc 2 Lapifuse, Inbone |
| Wright Medical Technology, INC. | $32,866.89 | 2019-2020 | |
| Organogenesis INC. | $24,425.28 | 2021-2025 | Puraply Wound Matrix, Affinity, Apligraf |
| Vilex LLC | $14,588.82 | 2023-2025 | Sri Lapidus |
| Treace Medical Concepts, INC. | $3,014.37 | 2022-2025 | |
| Smith+Nephew, INC. | $394.39 | 2020-2025 | Collagenase Santyl, Regranex, N/A |
| Novastep INC. | $367.90 | 2021-2022 | |
| Melinta Therapeutics, LLC | $180.41 | 2019 | |
| Nevro Corp. | $172.78 | 2022-2023 | Senza |
| Integra Lifesciences Corporation | $114.72 | 2019-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Orthofix Medical, INC. | $65.99 | 2020-2024 | Physio-Stim |
| Bioventus LLC | $50.70 | 2020-2025 | Exogen Ultrasound Bone Healing System |
| Nabriva Therapeutics, Plc | $47.03 | 2022 | |
| Acumed LLC | $46.33 | 2023 | Acumed, Osteomed |
| Reprise Biomedical, INC. | $44.72 | 2024-2025 | Miro3d |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $37.94 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $35.28 | 2019 | |
| Solventum Corporation | $34.88 | 2025 | Activ.A.C. |
| Abbvie INC. | $27.00 | 2024 | |
| Polynovo North America LLC | $26.97 | 2023 | |
| Amgen INC. | $25.85 | 2019 | |
| Zimmer Biomet Holdings, INC. | $22.41 | 2022 | |
| Depuy Synthes Sales INC. | $22.28 | 2023 | Na |
| Ethicon US, LLC | $20.09 | 2022 | |
| Triad Life Sciences INC. | $14.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.57 | 2019 | |
| Kci USA, INC. | $11.67 | 2021 | |
| Heron Therapeutics, INC. | $10.74 | 2022 | |
| Kerecis Limited | $10.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofie Pinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.